Coming May 2025
Get Early Access
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
87 employees
Solid Biosciences Inc., a US-based biotech firm, develops therapies and devices for muscular dystrophy.
HQ
Founded
2013
Solid Biosciences Inc., founded in the United States, is a biotechnology company dedicated to developing therapies and devices for patients with neuromuscular and cardiac diseases, with a particular focus on Duchenne muscular dystrophy. The company's core mission is to advance genetic medicines to improve the lives of those affected by these rare conditions. Solid Biosciences offers a portfolio of gene therapy candidates, including SGT-001 for Duchenne muscular dystrophy and other therapies targeting catecholaminergic polymorphic ventricular tachycardia.
Notable affiliated individuals include the company's founders and key scientific advisors who are leaders in the field of genetic medicine. Solid Biosciences has attracted significant investment from prominent venture capital firms and industry partners. Key achievements include advancing their lead gene therapy candidate, SGT-001, through various stages of clinical trials. The company's impact lies in its potential to bring transformative treatments to patients with debilitating neuromuscular diseases, addressing unmet medical needs and improving patient outcomes.
Operating Status
Active
Ownership Type(s)
Public
Main Product(s)
Gene Therapy, Therapies
Technology
Biotech
Tags
Biotech, Healthtech
Model Types
Software, Therapies
Revenue Type(s)
Recurring
Customer Type(s)
Enterprise, Healthcare
Geographic Exposure
United States
When was Solid Biosciences founded?
Solid Biosciences was founded in 2013.
Where is Solid Biosciences's headquarters located?
Solid Biosciences's headquarters is located in Cambridge, MA, US.
When was Solid Biosciences's last funding round?
Solid Biosciences's most recent funding round was for $75M (USD) in September 2022.
How many employees does Solid Biosciences have?
Solid Biosciences has 87 employees as of Feb 6, 2024.
How much has Solid Biosciences raised to-date?
As of July 05, 2023, Solid Biosciences has raised a total of $441.3M (USD) since Sep 30, 2022.
Add Comparison
Total Raised to Date
$441.3M
USD
Last Update Sep 30, 2022
Last Deal Details
$75M
USD
Sep 30, 2022
Post Ipo Equity
Current Employees
87
Last updated: Feb 6, 2024
No location information available for this company.
Locations
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts